Branch of medicine dealing with cancer
POPULARITY
Categories
Many cervical cancers are linked to the HPV virus. However, thanks to screening advancements, early detection of the cancer resulting in effective treatment is possible. Toni Kilts, DO, discusses screening guidelines and cervical cancer prevention.You can also watch the video recording on our Vimeo channel here.For more health tips & news you can use from experts you trust, sign up for Sarasota Memorial's monthly digital newsletter, Healthe-Matters.
How can pediatric and adult urologists team up to tackle complex cancer cases? In this episode of the BackTable Urology, host Dr. Amanda Buchanan, Division Chief of Pediatric Urology at the University of Kentucky, is joined by her colleagues Dr. Patrick Hensley, an adult urologic oncologist, and Dave Rodeberg, Division Chief of Pediatric Surgery. Their discussion centers around the importance of professional collaboration in urologic oncology care in order to improve patient outcomes.---SYNPOSISThe urologists discuss topics such as the experiences and benefits of interdisciplinary collaboration in complex cases and the role of pediatric urologists in treating adolescent and young adult patients. They also provide insights into the Children's Oncology Group (COG) studies and their intersections with adult oncology research. The episode concludes with practical advice for other institutions aiming to improve collaborative efforts between pediatric and adult urology departments.---TIMESTAMPS00:00 - Introduction02:35 - Challenges and Lessons in Multidisciplinary Collaboration08:24 - Pediatric vs. Adult Urologic Oncology11:07- Clinical Trials and Research Collaborations12:49 - Navigating Oncology Groups for Children and Adults19:06 - Collaborative Models in Kidney Cancer Care22:18 - Benefits and Challenges of Collaboration35:24 - Final Thoughts and Recommendations---RESOURCESSociety of Urologic Oncology:https://suonet.org/home.aspxChildren's Oncology Grouphttps://www.childrensoncologygroup.org/
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/CBJ865. CME/AAPA/IPCE credit will be available until May 27, 2026.Personalizing Prostate Cancer Care: Real-World Approaches for the Community Urology Practice In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and ZERO Prostate Cancer. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by educational grants from Astellas and Pfizer, Inc., Bayer HealthCare Pharmaceuticals Inc., and Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC (which are both Johnson & Johnson companies).Disclosure information is available at the beginning of the video presentation.
In this episode of the Manta Cares's Patient from Hell Podcast Club, host Mike Lynn engages with Sheila Goodrow, a metastatic breast cancer advocate, to discuss the importance of mental health resources for cancer patients. They explore Sheila's personal journey with cancer, the challenges of accessing mental health care, and the role of advocacy in healing. The conversation emphasizes the need for comprehensive support systems for patients and caregivers alike, highlighting the significance of mental wellness in the cancer journey.This Podcast Club accompanies Patient from Hell podcast Episode 84: Managing Insomnia and Mental Health in Cancer Care with Dr. Cara Bohon.00:00 Introduction to Patient Advocacy and Podcast Goals02:00 Sheila's Journey with Metastatic Breast Cancer03:52 Mental Health Challenges in Cancer Care09:46 Exploring Therapy and Mental Health Resources14:03 Accessibility of Mental Health Services for Patients17:58 The Role of Advocacy in Personal Healing19:59 Conclusion and Final Thoughts on WellnessConnect with Us:Enjoyed this episode? Make sure to subscribe, rate, and review! Follow us on Instagram, Facebook, or Linkedin @mantacares and visit our website at mantacares.com for more episodes and updates.Disclaimer:All content and information provided in connection with Manta Cares is solely intended for informational and educational purposes only. This content and information is not intended to be a substitute for medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition.This episode was supported by an award from the Patient-Centered Outcomes Research Institute.
Hematology-oncology physician Yousuf Zafar discusses his article, "The personalization of cancer care in 2025." He traces the evolution of cancer treatment over the past two decades, moving through waves of cytotoxic chemotherapy, biologic therapies, immunotherapies including groundbreaking CAR-T therapy, and now precision oncology, which targets treatments to the specific molecular profile of a patient's cancer. While these advancements have significantly improved survival and quality of life, Yousuf highlights the resulting increase in care complexity and the widening gap in outcomes between specialized centers (where only 20 percent of U.S. patients are treated) and community practices (where 80 percent of care occurs), particularly impacting rural areas where 66 percent of counties lack an oncologist. The conversation explores how digital health solutions, such as remote case reviews connecting community oncologists with subspecialists, can help bridge this divide and improve access. Importantly, Yousuf stresses that personalized care extends beyond treatment to encompass vital patient support for financial burdens, mental well-being, and survivorship. Actionable takeaways emphasize the need for collaboration, resources for community oncologists, investment in digital health tools, and a continued focus on patient-centered support throughout the cancer journey. Our presenting sponsor is Microsoft Dragon Copilot. Microsoft Dragon Copilot, your AI assistant for clinical workflow, is transforming how clinicians work. Now you can streamline and customize documentation, surface information right at the point of care, and automate tasks with just a click. Part of Microsoft Cloud for Healthcare, Dragon Copilot offers an extensible AI workspace and a single, integrated platform to help unlock new levels of efficiency. Plus, it's backed by a proven track record and decades of clinical expertise—and it's built on a foundation of trust. It's time to ease your administrative burdens and stay focused on what matters most with Dragon Copilot, your AI assistant for clinical workflow. VISIT SPONSOR → https://aka.ms/kevinmd SUBSCRIBE TO THE PODCAST → https://www.kevinmd.com/podcast RECOMMENDED BY KEVINMD → https://www.kevinmd.com/recommended
Are you or a loved one facing a diagnosis of bladder cancer, melanoma, or skin cancer? Tune in to this essential episode of Navigating Cancer TOGETHER for expert guidance and compassionate insights. Join host Talaya Dendy as she welcomes back Dr. Thomas Eanelli, a highly respected radiation oncologist based in New York. We also feature Angel Santana, co-host of The CROC Podcast, sharing powerful motivational perspectives. In observance of May Cancer Awareness, this special episode dives into critical aspects of three specific cancers: bladder, melanoma, and skin cancer. Dr. Eanelli provides invaluable medical expertise on the latest cancer treatments, diagnosis, and management of these diseases. Angel Santana offers heartfelt inspiration and emphasizes the power of support and positivity throughout the cancer journey. This episode is packed with vital information and moving stories to offer hope and guidance for anyone navigating cancer.
See omnystudio.com/listener for privacy information.
Dr. Leigh Erin Connealy is a globally recognized leader in integrative and functional medicine. She is the founder of the Center for New Medicine and Center for Healing in Irvine, California—two of the largest and most advanced integrative medical clinics in the country. With over 39 years of experience, Dr. Connealy specializes in treating chronic illness and cancer by combining the best of conventional science with natural healing and patient-centered care. Dr. Leigh Erin Connealy joins us for one of the most important health conversations we've had to date. With nearly four decades at the forefront of integrative cancer care, Dr. Connealy breaks down why chronic illness, cancer, and emotional dysfunction are exploding—and how to reverse the trend by taking radical responsibility for your health. She unpacks her holistic approach to healing—from foundational lifestyle habits like sleep, food, and detox to the spiritual and emotional work often ignored by mainstream medicine. What we cover: - Why self-care is the new healthcare- The great poisoning: environmental toxins and chronic illness- Foundational habits: sleep, clean food, movement, and hydration- Preventative testing and how to truly screen for disease- Why community is medicine and loneliness is a silent killerTimestamps: (00:00) Introduction (04:50) A generational health awakening (07:15) Fertility decline as warning sign (10:25) Sleep, water, food, and movement (16:40) Healing emotional trauma (23:30) Detox tools you can use (29:45) You are your own clinical trial (36:00) Redefining spirituality and health (41:25) Human connection as medicine (57:15) Preventative care done right *** LINKS***Check out our supplement company - Noble Origins- 100% grass-fed beef protein with added collagen, colostrum and organs- Use code MAFIA25 for 25% OFF your orderCheck out our Newsletter - Food for Thought - to dramatically improve your health this year!Join The Meat Mafia community Telegram group for daily conversations to keep up with what's happening between episodes of the show. Connect with Dr. Connealy:InstagramWebsite Connect with Brett:InstagramConnect with Harry:InstagramXConnect with Meat Mafia:Instagram - Meat MafiaX - Meat MafiaYouTube - Meat MafiaConnect with Noble Protein:Website - Noble ProteinX - Noble ProteinInstagram - Noble ProteinAFFILIATESLMNT - Electrolyte salts to supplement minerals on low-carb dietThe Carnivore Bar - Use Code 'MEATMAFIA' for 10% OFF - Delicious & convenient Pemmican BarPerennial Pastures - Use CODE 'MEATMAFIA' 10% OFF - Regeneratively raised, grass-fed & grass-finished beef from California & MontanaFarrow Skincare - Use CODE 'MEATMAFIA' at checkout for 20% OFFHeart & Soil - CODE ‘MEATMAFIA' for 10% OFF - enhanced nutrition to replace daily vitamins!Carnivore Snax - Use CODE 'MEATMAFIA' Crispy, airy meat chips that melt in your mouth. Regeneratively raised in the USA.Pluck Seasoning - 15% OFF - Nutrient-dense seasoning with INSANE flavor! Use CODE: MEATMAFIAWe Feed Raw 25% OFF your first order - ancestrally consistent food for your dog! Use CODE 'MEATMAFIA'Fond Bone Broth - 15% OFF - REAL bone broth with HIGH-QUALITY ingredients! It's a daily product for us! Use CODE: MAFIAMaui Nui- 15% OFF. Use CODE: MEATMAFIA
Host Dr. Nate Pennell and his guest, Dr. Chloe Atreya, discuss the ASCO Educational Book article, “Integrative Oncology: Incorporating Evidence-Based Approaches to Patients With GI Cancers,” highlighting the use of mind-body approaches, exercise, nutrition, acupuncture/acupressure, and natural products. Transcript Dr. Nate Pennell: Welcome to ASCO Education: By the Book, our new monthly podcast series that will feature engaging discussions between editors and authors from the ASCO Educational Book. We'll be bringing you compelling insights on key topics featured in Education Sessions at ASCO meetings and some deep dives on the approaches shaping modern oncology. I'm Dr. Nate Pennell, director of the Cleveland Clinic Lung Cancer Medical Oncology Program as well as vice chair of clinical research for the Taussig Cancer Institute. Today, I'm delighted to welcome Dr. Chloe Atreya, a professor of Medicine in the GI Oncology Group at the University of California, San Francisco, Helen Diller Family Comprehensive Cancer Center, and the UCSF Osher Center for Integrative Health, to discuss her article titled, “Integrative Oncology Incorporating Evidence-Based Approaches to Patients With GI Cancers”, which was recently published in the ASCO Educational Book. Our full disclosures are available in the transcript of this episode. Dr. Atreya, it's great to have you on the podcast today. Thanks for joining me. Dr. Chloe Atreya: Thanks Dr. Pennell. It's a pleasure to be here. Dr. Nate Pennell: Dr. Atreya, you co-direct the UCSF Integrative Oncology Program with a goal to really help patients with cancer live as well as possible. And before we dive into the review article and guidelines, I'd love to just know a little bit about what inspired you to go into this field? Dr. Chloe Atreya: Yeah, thank you for asking. I've had a long-standing interest in different approaches to medicine from global traditions and I have a degree in pharmacology, and I continue to work on new drug therapies for patients with colorectal cancer. And one thing that I found is that developing new drugs is a long-term process and often we're not able to get the drugs to the patients in front of us. And so early on as a new faculty member at UCSF, I was trying to figure out what I could do for the patient in front of me if those new drug therapies may not be available in their lifetime. And one thing I recognized was that in some conversations the patient and their family members, even if the patient had metastatic disease, they were able to stay very present and to live well without being sidelined by what might happen in the future. And then in other encounters, people were so afraid of what might be happening in the future, or they may have regrets maybe about not getting that colonoscopy and that was eroding their ability to live well in the present. So, I started asking the patients and family members who were able to stay present, “What's your secret? How do you do this?” And people would tell me, “It's my meditation practice,” or “It's my yoga practice.” And so, I became interested in this. And an entry point for me, and an entry point to the Osher Center at UCSF was that I took the Mindfulness-Based Stress Reduction Program to try to understand experientially the evidence for this and became very interested in it. I never thought I would be facilitating meditation for patients, but it became a growing interest. And as people are living longer with cancer and are being diagnosed at younger ages, often with young families, how one lives with cancer is becoming increasingly important. Dr. Nate Pennell: I've always been very aware that it seemed like the patients that I treated who had the best quality of life during their life with cancer, however that ended up going, were those who were able to sort of compartmentalize it, where, when it was time to focus on discussing treatment or their scans, they were, you know, of course, had anxiety and other things that went along with that. But when they weren't in that, they were able to go back to their lives and kind of not think about cancer all the time. Whereas other people sort of adopt that as their identity almost is that they are living with cancer and that kind of consumes all of their time in between visits and really impacts how they're able to enjoy the rest of their lives. And so, I was really interested when I was reading your paper about how mindfulness seemed to be sort of like a formal way to help patients achieve that split. I'm really happy that we're able to talk about that. Dr. Chloe Atreya: Yeah, I think that's absolutely right. So, each of our patients is more than their cancer diagnosis. And the other thing I would say is that sometimes patients can use the cancer diagnosis to get to, “What is it that I really care about in life?” And that can actually heighten an experience of appreciation for the small things in life, appreciation for the people that they love, and that can have an impact beyond their lifetime. Dr. Nate Pennell: Just in general, I feel like integrative medicine has come a long way, especially over the last decade or so. So, there's now mature data supporting the incorporation of elements of integrative oncology into comprehensive cancer care. We've got collaborations with ASCO. They've published clinical practice guidelines around diet, around exercise, and around the use of cannabinoids. ASCO has worked with the Society for Integrative Oncology to address management of pain, anxiety, depression, fatigue – lots of different evidence bases now to try to help guide people, because this is certainly something our patients are incredibly interested in learning about. Can you get our listeners up to speed a little bit on the updated guidelines and resources supporting integrative oncology? Dr. Chloe Atreya: Sure. I can give a summary of some of the key findings. And these are rigorous guidelines that came together by consensus from expert panels. I had the honor of serving on the anxiety and depression panel. So, these panels will rate the quality of the evidence available to come up with a strength of recommendation. I think that people are at least superficially aware of the importance of diet and physical activity and that cannabis and cannabinoids have evidence of benefit for nausea and vomiting. They may not be aware of some of the evidence supporting these other modalities. So, for anxiety and depression, mindfulness-based interventions, which include meditation and meditative movement, have the strongest level of evidence. And the clinical practice guidelines indicate that they should be offered to any adult patient during or after treatment who is experiencing symptoms of anxiety or depression. Other modalities that can help with anxiety and depression include yoga and Tai Chi or Qigong. And with the fatigue guidelines, mindfulness-based interventions are also strongly recommended, along with exercise and cognitive behavioral therapy, Tai Chi and Qigong during treatment, yoga after treatment. And some of these recommendations also will depend on where the evidence is. So, yoga is an example of an intervention that I think can be helpful during treatment, but most of our evidence is on patients who are post-treatment. So, most of our guidelines separate out during treatment and the post-treatment phase because the quality of evidence may be different for these different phases of treatment. With the pain guidelines, the strongest recommendation is for acupuncture, specifically for people with breast cancer who may be experiencing joint pain related to aromatase inhibitors. However, acupuncture and other therapies, including massage, can be helpful with pain as well. So those are a few of the highlights. Dr. Nate Pennell: Yeah, I was surprised at the really good level of evidence for the mindfulness-based practices because I don't think that's the first thing that jumps to mind when I think about integrative oncology. I tend to think more about physical interventions like acupuncture or supplements or whatnot. So, I think this is really fantastic that we're highlighting this. And a lot of these interventions like the Qigong, Tai Chi, yoga, is it the physical practice of those that benefits them or is it that it gives them something to focus on, to be mindful of? Is that the most important intervention? It doesn't really matter what you're doing as long as you have something that kind of takes you out of your experience and allows you to focus on the moment. Dr. Chloe Atreya: I do think it is a mind, body and spirit integration, so that all aspects are important. We also say that the best practice is the one that you actually practice. So, part of the reason that it's important to have these different modalities is that not everybody is going to take up meditation. And there may be people for whom stationary meditation, sitting and meditating, works well, and other people for whom meditative movement practices may be what they gravitate to. And so, I think that it's important to have a variety of options. And one thing that's distinct from some of our pharmacologic therapies is that the safety of these is, you know, quite good. So, it becomes less important to say, “Overall, is Tai Chi better or is yoga better?” for instance. It really depends on what it is that someone is going to take up. Dr. Nate Pennell: And of course, something that's been really nice evidence-based for a long time, even back when I was in my training in the 2000s with Jennifer Temel at Massachusetts General Hospital, was the impact of physical activity and exercise on patients with cancer. It seems like that is pretty much a universally good recommendation for patients. Dr. Chloe Atreya: Yes, that's absolutely right. Physical activity has been associated with improved survival after a cancer diagnosis. And that's both cancer specific survival and overall survival. The other thing I'll say about physical activity, especially the mindful movement practices like Tai Chi and Qigong and yoga, is that they induce physiologic shifts in the body that can promote relaxation, so they can dampen that stress response in a physiologic way. And these movement practices are also the best way to reduce cancer-associated fatigue. Dr. Nate Pennell: One of the things that patients are always very curious about when they talk to me, and I never really feel like I'm as well qualified as I'd like to be to advise them around dietary changes in nutrition. And can you take me a little bit through some of the evidence base for what works and what doesn't work? Dr. Chloe Atreya: Sure. I do think that it needs to be tailored to the patient's needs. Overall, a diet that is plant-based and includes whole grains is really important. And I often tell patients to eat the rainbow because all of those different phytochemicals that cause the different colors in our fruits and vegetables are supporting different gut microbiota. So that is a basis for a healthy gut microbiome. That said, you know, if someone is experiencing symptoms related to cancer or cancer therapy, it is important to tailor dietary approaches. This is where some of the mindful eating practices can help. So, sometimes actually not just focusing on what we eat, but how we eat can help with symptoms that are associated with eating. So, some of our patients have loss of appetite, and shifting one's relationship to food can help with nutrition. Sometimes ‘slow it down' practices can help both with appetite and with digestion. Dr. Nate Pennell: One of the things that you said both in the paper and just now on our podcast, talking about how individualized and personalized this is. And I really liked the emphasis that you had on flexibility and self-compassion over rigid discipline and prescriptive recommendations here. And this is perhaps one of the real benefits of having an integrative oncology team that can work with patients as opposed to them just trying to find things online. Dr. Chloe Atreya: Yes, particularly during treatment, I think that's really important. And that was borne out by our early studies we called “Being Present.” So, after I was observing the benefits anecdotally among my patients of the ability to be present, we designed these pilot studies to teach meditation and meditative practices to patients. And in these pilot studies, the original ones were pretty prescriptive in a way that mindfulness-based stress reduction is fairly prescriptive in terms of like, “This is what we're asking you to do. Just stick with the program.” And there can be benefits if you can stick with the program. It's really hard though if someone is going through treatment and with GI cancers, it may be that they're getting chemotherapy every two weeks and they have one week where they're feeling really crummy and another week where they're trying to get things done. And we realized that sometimes people were getting overwhelmed and feeling like the mindfulness practice was another thing on their to-do list and that they were failing if they didn't do this thing that was important for them. And so, we've really kind of changed our emphasis. And part of our emphasis now is on incorporating mindfulness practices into daily life. Any activity that doesn't require a lot of executive function can be done mindfully, meaning with full attention. And so, especially for some of our very busy patients, that can be a way of, again, shifting how I'm doing things rather than adding a new thing to do. Dr. Nate Pennell: And then another part I know that patients are always very curious about that I'm really happy to see that we're starting to build an evidence base for is the use of supplements and natural products. So, can you take us a little bit through where we stand in terms of evidence behind, say, cannabis and some of the other available products out there? Dr. Chloe Atreya: Yeah, I would say that is an area that requires a lot more study. It's pretty complicated because unlike mindfulness practices where there are few interactions with other treatments, there is the potential for interactions, particularly with the supplements. And the quality of the supplements matters. And then there tends to be a lot of heterogeneity among the studies both in the patients and what other treatments they may be receiving, as well as the doses of the supplements that they're receiving. One of my earliest mentors at Yale is someone named Dr. Tommy Chang, who has applied the same rigor that that we apply to testing of biomedical compounds to traditional Chinese medicine formulas. And so, ensuring that the formulation is stable and then formally testing these formulations along with chemotherapy. And we need more funding for that type of research in order to really elevate our knowledge of these natural products. We often will direct patients to the Memorial Sloan Kettering ‘About Herbs, Botanicals, and Other Products' database as one accessible source to learn more about the supplements. We also work with our pharmacists who can provide the data that exists, but we do need to take it with a grain of salt because of the heterogeneity in the data. And then it's really important if people are going to take supplements, for them to take supplements that are of high quality. And that's something in the article that we list all of the things that one should look for on the label of a supplement to ensure that it is what it's billed to be. Dr. Nate Pennell: So, most of what we've been talking about so far has really been applying to all patients with cancer, but you of course are a GI medical oncologist, and this is a publication in the Educational Book from the ASCO GI Symposium. GI cancers obviously have an incredibly high and rising incidence rate among people under 50, representing a quarter of all cancer incidence worldwide, a third of cancer related deaths worldwide. Is there something specific that GI oncologists and patients with GI cancers can take home from your paper or is this applicable to pretty much everyone? Dr. Chloe Atreya: Yeah, so the evidence that we review is specifically for GI cancers. So, it shows both its strengths and also some of the limitations. So many of the studies have focused on other cancers, especially breast cancer. In the integrative oncology field, there are definitely gaps in studying GI cancers. At the same time, I would say that GI cancers are very much linked to lifestyle in ways that are complicated, and we don't fully understand. However, the best ways that we can protect against development of GI cancers, acknowledging that no one is to blame for developing a GI cancer and no one is fully protected, but the best things that we can do for overall health and to prevent GI cancers are a diet that is plant-based, has whole grains. There's some data about fish that especially the deep-water fish, may be protective and then engaging in physical activity. One thing I would like for people to take away is that these things that we know that are preventative against developing cancer are also important after development of a GI cancer. Most of the data comes from studies of patients with colorectal cancer and that again, both cancer specific and overall mortality is improved with better diet and with physical activity. So, this is even after a cancer diagnosis. And I also think that, and this is hard to really prove, but we're in a pretty inflammatory environment right now. So, the things that we can do to decrease stress, improve sleep, decrease inflammation in the body, and we do know that inflammation is a risk factor for developing GI cancers. So, I think that all of the integrative modalities are important both for prevention and after diagnosis. Dr. Nate Pennell: And one of the things you just mentioned is that most of the studies looking at integrative oncology and GI cancers have focused on colorectal cancer, which of course, is the most common GI cancer. But you also have pointed out that there are gaps in research and what's going on and what needs to be done in order to broaden some of this experience to other GI cancers. Dr. Chloe Atreya: Yeah, and I will say that there are gaps even for colorectal cancer. So right now, some of the authors on the article are collaborating on a textbook chapter for the Society for Integrative Oncology. And so, we're again examining the evidence specifically for colorectal cancer and are in agreement that the level of evidence specific to colorectal cancer is not as high as it is for all patients with adult cancers. And so even colorectal cancer we need to study more. Just as there are different phases of cancer where treatments may need to be tailored, we also may need to tailor our treatments for different cancer types. And that includes what symptoms the patients are commonly experiencing and how intense the treatment is, and also the duration of treatment. Those are factors that can influence which modalities may be most important or most applicable to a given individual. Dr. Nate Pennell: So, a lot of this sounds fantastic. It sounds like things that a lot of patients would really appreciate working into their care. Your article focused a little bit on some of the logistics of providing this type of care, including group medical visits, multidisciplinary clinics staffed by multiple types of clinicians, including APPs and psychologists, and talked about the sustainability of this in terms of increasing the uptake of guideline-based integrative oncology. Talk a little bit more about both at your institution, I guess, and the overall health system and how this might be both sustainable and perhaps how we broaden this out to patients outside of places like UCSF. Dr. Chloe Atreya: Yes, that's a major focus of our research effort. A lot of comprehensive cancer centers and other places where patients are receiving care, people may have access to dietitians, which is really important and nutritionists. In the article we also provide resources for working with exercise therapists and those are people who may be working remotely and can help people, for instance, who may be in, in rural areas. And then our focus with the mind-body practices in particular has been on group medical visits. And this grew out of, again, my ‘being present' pilot studies where we were showing some benefit. But then when the grant ends, there isn't a way to continue to deliver this care. And so, we were asking ourselves, you know, is there a way to make this sustainable? And group medical visits have been used in other settings, and they've been working really well at our institution and other institutions are now taking them up as well. And this is a way that in this case it's me and many of my colleagues who are delivering these, where I can see eight or ten patients at once. In my case, it's a series of four two-hour sessions delivered by telehealth. So, we're able to focus on the integrative practices in a way that's experiential. So, in the clinic I may be able to mention, you know, after we go over the CT scans, after we go over the labs and the molecular profiling, you know, may be able to say, “Hey, you know, meditation may be helpful for your anxiety,” but in the group medical visits we can actually practice meditation, we can practice chair yoga. And that's where people have that experience in their bodies of these different modalities. And the feedback that we're receiving is that that sticks much more to experience it then you have resources to continue it. And then the group is helpful both in terms of delivery, so timely and efficient care for patients. It's also building community and reducing the social isolation that many of our patients undergoing treatment for cancer experience. Dr. Nate Pennell: I think that makes perfect sense, and I'm glad you brought up telehealth as an option. I don't know how many trained integrative oncologists there are out there, but I'm going to guess this is not a huge number out there. And much like other specialties that really can improve patients' quality of life, like palliative medicine, for example, not everyone has access to a trained expert in their cancer center, and things like telemedicine and telehealth can really potentially broaden that. How do you think telehealth could help broaden the exposure of cancer patients and even practitioners of oncology to integrative medicine? Dr. Chloe Atreya: Yes, I think that telehealth is crucial for all patients with cancer to be able to receive comprehensive cancer care, no matter where they're receiving their chemotherapy or other cancer-directed treatments. So, we will routinely be including patients who live outside of San Francisco. Most of our patients live outside of San Francisco. There's no way that they could participate if they had to drive into the city again to access this. And in the group setting, it's not even safe for people who are receiving chemotherapy to meet in a group most times. And with symptoms, often people aren't feeling so well and they're able to join us on Zoom in a way that they wouldn't be able to make the visit if it was in person. And so, this has really allowed us to expand our catchment area and to include patients, in our case, in all of California. You also mentioned training, and that's also important. So, as someone who's involved in the [UCSF] Osher Collaborative, there are faculty scholars who are at universities all over the US, so I've been able to start training some of those physicians to deliver group medical visits at their sites as well via telehealth. Dr. Nate Pennell: I'm glad we were able to make a plug for that. We need our political leadership to continue to support reimbursement for telehealth because it really does bring access to so many important elements of health care to patients who really struggle to travel to tertiary care centers. And their local cancer center can be quite a distance away. So, sticking to the theme of training, clinician education and resources are really crucial to continue to support the uptake of integrative oncology in comprehensive cancer care. Where do you think things stand today in terms of clinician education and professional development in integrative oncology. Dr. Chloe Atreya: It's growing. Our medical students now are receiving training in integrative medicine, and making a plug for the Educational Book, I was really happy that ASCO let us have a table that's full of hyperlinks. So that's not typical for an article. Usually, you have to go to the reference list, but I really wanted to make it practical and accessible to people, both the resources that can be shared with patients that are curated and selected that we thought were of high-quality examples for patients. At the bottom of that table also are training resources for clinicians, and some of those include: The Center for Mind-Body Medicine, where people can receive training in how to teach these mind-body practices; The Integrated Center for Group Medical Visits, where people can learn how to develop their own group medical visits; of course, there's the Society for Integrative Oncology; and then I had just mentioned the Osher Collaborative Faculty Fellowship. Dr. Nate Pennell: Oh, that is fantastic. And just looking through, I mean, this article is really a fantastic resource both of the evidence base behind all of the elements that we've discussed today. Actually, the table that you mentioned with all of the direct hyperlinks to the resources is fantastic. Even recommendations for specific dietary changes after GI cancer diagnosis. So, I highly recommend everyone read the full paper after they have listened to the podcast today. Before we wrap up, is there anything that we didn't get a chance to discuss that you wanted to make sure our listeners are aware of? Dr. Chloe Atreya: One thing that I did want to bring up is the disparities that exist in access to high quality symptom management care. So, patients who are racial and ethnic minorities, particularly our black and Latinx patients, the evidence shows that they aren't receiving the same degree of symptom management care as non-Hispanic White patients. And that is part of what may be leading to some of the disparities in cancer outcomes. So, if symptoms are poorly managed, it's harder for patients to stay with the treatment, and integrative oncology is one way to try to, especially with telehealth, this is a way to try to improve symptom management for all of our patients to help improve both their quality of life and their cancer outcomes. Dr. Nate Pennell: Well, Dr. Atreya, it's been great speaking with you today and thank you for joining me on the ASCO Education: By the Book Podcast and thank you for all of your work in advancing integrative oncology for GI cancers and beyond. Dr. Chloe Atreya: Thank you, Dr. Pennell. It's been a pleasure speaking with you. Dr. Nate Pennell: And thank you to all of our listeners who joined us today. You'll find a link to the article discussed today in the transcript of the episode. We hope you'll join us again for more insightful views on topics you'll be hearing at the Education Sessions from ASCO meetings throughout the year and our deep dives on approaches that are shaping modern oncology. Disclaimer: The purpose of this podcast is to educate, educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement. Follow today's speakers: Dr. Nathan Pennell @n8pennell @n8pennell.bsky.social Dr. Chloe Atreya Follow ASCO on social media: @ASCO on X (formerly Twitter) ASCO on Bluesky ASCO on Facebook ASCO on LinkedIn Disclosures: Dr. Nate Pennell: Consulting or Advisory Role: AstraZeneca, Lilly, Cota Healthcare, Merck, Bristol-Myers Squibb, Genentech, Amgen, G1 Therapeutics, Pfizer, Boehringer Ingelheim, Viosera, Xencor, Mirati Therapeutics, Janssen Oncology, Sanofi/Regeneron Research Funding (Institution): Genentech, AstraZeneca, Merck, Loxo, Altor BioScience, Spectrum Pharmaceuticals, Bristol-Myers Squibb, Jounce Therapeutics, Mirati Therapeutics, Heat Biologics, WindMIL, Sanofi Dr. Chloe Atreya: Consulting or Advisory Role: Roche Genentech, Agenus Research Funding (Institution): Novartis, Merck, Bristol-Myers Squibb, Guardant Health, Gossamer Bio, Erasca, Inc.
Join Rebeca Leon on this episode of the Nurse Converse podcast as she pulls back the curtain on the world of oncology nursing. She shares her personal journey into this life-changing specialty, reflecting on the emotional highs, the profound patient connections, and the powerful community of oncology nurses. Get inspired by highlights from the 50th Oncology Nursing Society Congress and discover why this field is more critical than ever. If you've ever wondered what it's like to make a difference in the lives of cancer patients, this episode is for you. >>Inside Oncology Nursing: Stories, Challenges & Triumphs from the Frontlines of Cancer CareJump Ahead to Listen: [01:08] Oncology Nursing Society's 50th anniversary.[05:10] Oncology nursing specialties and settings.[10:57] Oncology nurses' resilience and care.[13:57] Attending oncology nursing conferences.[17:51] Customizing conference experiences for nurses.[23:45] Immunotherapy in oncology nursing.[26:00] Advancements in oncology nursing.[30:07] Oncology nursing opportunities for students.[34:37] Oncology nursing community connection.Connect with Rebeca on Social Media:Instagram: @EnfermeraMami.RNFor more information, full transcript and videos visit Nurse.org/podcastJoin our newsletter at nurse.org/joinInstagram: @nurse_orgTikTok: @nurse.orgFacebook: @nurse.orgYouTube: Nurse.org
Navigating disparities in the diagnosis and treatment of biliary tract cancer (BTC) is essential for improving patient outcomes, ensuring equitable care, and optimizing the patient experience. The Association of Cancer Care Centers (ACCC) remains committed to increasing awareness and disseminating the latest strategies for BTC management. In this episode, CANCER BUZZ explores these issues with Paige Griffith, CRNP, lead oncology nurse practitioner at Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, who highlights the vital role of multidisciplinary teams in reducing care fragmentation and streamlining care delivery. CANCER BUZZ also speaks with Chaundra Bishop, a patient with biliary tract cancer, who shares her personal experience confronting systemic barriers—particularly delays and obstacles during the diagnostic process—and offers insights into how addressing such disparities can improve the patient journey for others. “Everyone plays a role, even from early-stage disease all the way to advanced disease, and having someone help navigate patients through that very complex system is important.” – Paige Griffith, CRNP “From the patient perspective, I think it's always important to ask for what you need, or ask questions if you don't understand something. Don't, as they say, suffer in silence.” – Chaundra Bishop Paige Griffith, CRNP Lead Oncology Nurse Practitioner Johns Hopkins Sidney Kimmel Comprehensive Cancer Center Baltimore, MD Chaundra Bishop Patient With Biliary Tract Cancer Resources: Bile Duct Cancer - MD Anderson Cancer Center - https://bit.ly/42YPRdT Cholangiocarcinoma - NCI - https://bit.ly/44oV4N2
In this episode, Dr. Paul Sieber and Ashley Rentisky, PA-C, are joined by Dr. Evan Goldfischer, past president of LUGPA, to address the underutilization of germline and tumor (somatic) testing somatic testing in prostate cancer management. They will discuss challenges practices face in integrating genetic testing into clinical workflows and offer strategies for overcoming barriers. Tune in for expert insights and actionable advice that can transform prostate cancer care! Send us a text
Christine Verini is a pharmacist by training, a nonprofit CEO by title, and an unapologetic empath by design. She now leads CancerCare, one of the oldest, least-known, and most impactful organizations in the country that actually helps real cancer patients deal with the practical garbage no one likes to talk about—like paying rent, affording a ride to chemo, or feeding their kids.We talk about her career pivot from industry to impact, what it's like trying to scale empathy without losing your soul, and the daily gut-punch of knowing there are millions of people who still have no idea that CancerCare exists. Christine gets real about leadership, advocacy, burnout, and why being “pan-cancer” matters more than ever in a world obsessed with biomarkers, buckets, and branding.She also dishes on what AI gets dead wrong, what patients actually want when they call for help, and why “ghosting” someone with cancer is still a thing. Buckle up. This one's packed with heart, brains, and a little righteous rage.RELATED LINKSCancerCareChristine Verini on LinkedInChristine's CEO Announcement – PR NewswireCancer Health 25: Christine VeriniChristine on HealthyWomenBIO Convention Speaker ProfileFEEDBACKLike this episode? Rate and review Out of Patients on your favorite podcast platform. For guest suggestions or sponsorship inquiries, email podcast@matthewzachary.comSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.
Discover the Power of Herbal Medicine in Cancer Care with Petra SovcovJoin host Ivelisse Page on the Believe Big podcast as she welcomes Petra Sovcov, a clinical herbal therapist and Doctor of Natural Medicine based in Vancouver, BC. Founder of Healing House Natural Wellness, Petra brings decades of experience helping patients with chronic inflammatory conditions, including cancer and autoimmune diseases. In this enlightening episode, Petra shares practical, science-backed insights on how herbal remedies can complement conventional care to support detoxification, emotional health, and mental clarity.Petra discusses:Why it's vital to slow down and make informed decisions in a health crisisHow to source high-quality herbs and read product labels wiselyWhich herbs are most effective for detox and emotional balanceHow herbal tinctures can enhance treatment outcomesWhether you're a patient, caregiver, or health advocate, this episode is full of actionable tips to naturally strengthen your healing journey.
Love the episode? Send us a text!In this episode of Breast Cancer Conversations, I, Laura Carfing, founder of survivingbreastcancer.org, delve into the critical topic of fertility preservation and genetic counseling for breast cancer patients. Joined by Alejandra Bernal, a genetic counseling student at the University of Pittsburgh, and Melissa Bourdius , a hereditary cancer counselor, we explore the intersection of cancer treatment, fertility, and genetics.Alejandra shares insights from her research on how patients are informed about the risk of infertility due to cancer treatments and the role genetic counselors can play in this process. She highlights the importance of asking the right questions and involving a multidisciplinary team to ensure patients receive comprehensive information about their options.Melissa discusses the genetic aspects of cancer, explaining how mutations in genes like BRCA1 and BRCA2 can increase cancer risk and affect family planning decisions. She emphasizes the importance of genetic counseling in helping patients understand their risks and make informed decisions about their treatment and future family planning.It's all here for you in today's episode! Resources:https://www.facingourrisk.org/support/insurance-paying-for-care/screening-and-prevention/fertility-preservation/overviewhttps://www.allianceforfertilitypreservation.org/fertility-risks-from-treatment/https://www.thechickmission.org/ Information about grants and advocacyhttps://worththewaitcharity.com/resources/patient-education/ Has practical patient resourcesSURVIVINGBREASTCANCER.ORGAttend a free virtual SurvivingBreastCancer.org event:https://www.survivingbreastcancer.org/eventsFollow us on InstagramSurvivingBreastCancer.org: https://www.survivingbreastcancer.org/Breast Cancer Conversations: https://www.instagram.com/breastcancerconversations/About SurvivingBreastCancer.org: SurvivingBreastCancer.org, Inc. (SBC) is a federally recognized 501(c)(3) non-profit virtual platform headquartered in Boston with a national and global reach. Through education, community, and resources, SurvivingBreastCancer.org supports women and men going through breast cancer. We provide a sanctuary of strength, compassion, and empowerment, where those diagnosed with cancer unite to share their stories, learn invaluable coping strategies to manage wellness and mental health, and find solace in the unbreakable bond that fuels hope, resilience, and the courage to conquer adversity.Support the show
The alarming rise of early-onset cancers, particularly in individuals under 50, demands a critical shift in our understanding and approach to cancer care. In this episode, Dr. Karin Tollefson, Chief Oncology Medical Officer at Pfizer, discusses the concerning 79% increase in cancer diagnoses among younger people since 1990, highlighting the urgent need to address this trend. She emphasizes that this is a multifactorial issue, with likely contributors including Western lifestyle factors such as poor diet, obesity, sedentary habits, and exposure to toxins, as well as genetic predispositions. Dr. Tollefson also underscores the need for increased screening accessibility, particularly with colonoscopies, and molecular testing to tailor treatments for younger patients often diagnosed at later stages. Furthermore, she addresses the importance of making clinical trials more accessible to diverse populations and ensuring comprehensive survivorship care, including mental health, family planning, and fertility considerations, as cancer survival rates increase. Finally, Dr. Tollefson calls on the need to partner with advocacy organizations and to educate the public about early detection, healthy lifestyles, and available resources. Tune in and learn about the critical shifts needed in cancer care to address early-onset cases. Resources: Follow Dr. Karin Tollefson, Chief Oncology Medical Officer at Pfizer, on LinkedIn. Discover more about Pfizer on their LinkedIn and website. Read more on Pfizer in Oncology here. Patient Resources/Advocacy Links: Explore This Is Living With Cancer's Advocacy Support's website. Visit the Global Colorectal Cancer Alliance's website here. (Pfizer was one of their sponsors) Learn more about the transformative work CancerCare is doing. Find CancerCare's guide on Biomarker Testing here. Read the best practices for Biomarker Testing Coverage here. (Pfizer had input and was a sponsor) Get AONN Biomarker Navigation here. For the Precision Medicine Toolkit, look here. Empower yourself or your patients with essential navigation resources–a site co-created with AONN, to find materials on breast, prostate, health equity, geriatric, and more. (Patient navigators can download and share educational tools for enhanced support.) Deepen your understanding of prostate cancer here.
Core and Purple House Cancer Support launch 'Cancer Care at Work', an initiative that will provide practical advice and guidance for employers who want to create or enhance their cancer support policy Seven in ten employees (73%) feel a cancer diagnosis negatively impacts career progression, while over half (57%) of employees who have had cancer confirm this Two thirds (67%) say the existence of a cancer support policy would influence their decision to work at a company 88% of employees believe that a workplace cancer policy is important, but only 19% say their company has one, according to new research from Core, Ireland's largest marketing communications company, in partnership with Purple House Cancer Support, a leading cancer support centre in Ireland. The research, which gathered insights from 1,000 members of the general public, 85 employers across various sectors in Ireland, and employees who have experienced cancer in the workplace, also revealed that over seven in ten (73%) believe a cancer diagnosis negatively impacts career progression with over half (57%) of employees who have had cancer confirming this. Does your company have a workplace cancer policy? The research, unveiled today, also shows that 91% of employers expressed a willingness to implement cancer support policies, yet fewer than one in five companies currently have one in place. Two thirds (67%) also said that the existence of a cancer support policy would influence their decision to work at a company. To address this, Core and Purple House Cancer Support, the first ever community-based cancer support centre in Ireland, have launched 'Cancer Care at Work', a framework which will enable employers and businesses to create a policy and support system for employees who receive a cancer diagnosis or are supporting a loved one undergoing treatment. Companies can learn more or sign up at https://www.cancercareatwork.com/ The research also identifies four key areas employees would like included in a workplace cancer policy: 1. Emotional Support: Counselling services, workplace culture pledges, and peer support groups were among the most sought-after supports and seen as highly feasible by employers 2. Physical Support: Flexible treatment accommodations, fitness & rehabilitation programmes, and nutritional support rank highly, but employees stress the need for choice and autonomy in these supports 3. Education & Awareness: Training for people managers is one of the key supports that both employers and employees would like to have access to 4. Financial Support: Employees highly value Private Health Insurance membership, health insurance upgrades, and financial counselling The research also revealed that: Half of adults would feel uncomfortable disclosing a diagnosis to an employer (49% of all adults with 13% not sure) On the upside, seven in ten feel their employers would be supportive (73%) Main concerns for those who had / have cancer and are working, centred around financial concerns, job security and recover 67% of Irish people say that a set policy designed to support cancer patients would influence their decision to work there Only 25% of employers believe their management teams are adequately trained to handle a cancer diagnoses within the workforce, highlighting a lack of preparedness among employers which could result in a number of challenges for employees undergoing or recovering from treatment. Nicola Gillen, Chief of Staff at Core, said: "With one in two people likely to receive a diagnosis in their lifetime, it is imperative that employers introduce policies that support employees undergoing a cancer diagnosis or treatment. This research confirms what many employees living with cancer already know - while workplaces want to help, the policies and structures simply aren't there, A Cancer Care at Work Policy is not just a 'nice to have' - it is a business and human imperative. By asking employers to participate, we are breaking down any stigma ass...
Send us a textWelcome to Episode 29 of The Oncology Podcast's Experts On Point series, brought to you by The Oncology Network. Hosted by Rachael Babin.How do we tackle inequities in cancer care? What role do collaborative networks play in ensuring better outcomes for patients and their families? And how can molecular tumour boards bridge the gap for those outside metropolitan areas, giving them access to life-saving treatments and clinical trials?To explore these critical questions, our Host Rachael Babin is joined by Professor Mark Shackleton—Director of Oncology at Alfred Health, Professor of Oncology at Monash University, Chair of Melanoma and Skin Cancer Trials Ltd, and Co-Director of the Monash Partners Comprehensive Cancer Consortium (MPCCC).The Monash Partners Comprehensive Cancer Consortium (MPCCC) is transforming cancer care by creating networks that ensure equitable access to precision oncology across Victoria, regardless of a patient's location.Did You Know?• The MPCCC Fellowship program embeds early-career oncologists in partner hospitals to build expertise and connections• The Precision Oncology Program has processed over 1,000 patient referrals• 20% of referred patients receive recommendations for targeted therapies matched to their cancer's molecular profile• 5% of patients connected to clinical trials they wouldn't otherwise access• Regular molecular tumour boards discuss 5-10 cases per session• MPCCC has delivered a significant increase in regional cancer patient referrals, especially from GippslandVisit our website for information on the simple referral process through the Omico CaSP program and access this incredible resource for your patients. So, let's dive into the groundbreaking work being done to break down barriers and expand access to precision oncology.We hope you enjoy listening.For news and podcast updates subscribe to The Oncology Newsletter, a free weekly publication for healthcare professionals with an interest in oncology. Click here to subscribe.PART OF THE ONCOLOGY NETWORK... Join Us
In AARC's latest AARC Perspectives Podcast - Behind the Breath: A Day in the Life of a Cancer Care RT, we are joined by Michelle Rausen, MS, RRT, RRT-NPS, RRT-ACCS of Memorial Sloan Kettering Cancer Center and AARC VP of Membership and Customer Care, Monique Kimmel. Michelle discusses her insights, the emotional and psychological aspects of her work, why RTs in cancer-specific care are so critical, and how AARC is helping to bring the cancer care community together. Additional Resources:AARC Connect Cancer Care CommunityYouTube Live RecordingAbout our guest - Michelle Raussen, MS, RRT, RRT-NPS, RRT-ACCSSend us a textSupport the show
Conor O'Leary, Director of Operations at Purple House Cancer Support // Nicola Gillen, Chief of Staff at Core and breast cancer survivor // Katie Boylan, colon cancer survivor
Antibody-drug conjugates (ADCs) are novel therapeutic agents designed to target specific tumor markers with potent anticancer drugs. The Association of Cancer Care Centers (ACCC) is dedicated to providing up-to-date information on ADC treatment management. In this episode, CANCER BUZZ speaks with Nancy Mallett, a patient advocate, to discuss the patient's perspective and experience receiving treatment for gynecologic cancers, particularly with ADCs such as mirvetuximab soravtansine-gynx. “[Providers] giving me the information and allowing us to decide together, instead of just telling me, makes me feel more cared about and that I'm not just a number, I'm a person. They care about what I think, and look at my life and what it can do for me.” – Nancy Mallett Nancy Mallett Patient Advocate Resources: FDA Approval Summary: Mirvetuximab soravtansine-gynx for FRα-positive, Platinum-Resistant Ovarian Cancer - https://bit.ly/4is00nD Society of Gynecologic Oncology (SGO): Gynecologic Cancer Resources for Patients and Their Families - https://bit.ly/4jpYaoP ASCO: Antibody-Drug Conjugates in Gynecologic Cancer - https://bit.ly/42GP5k8 Society of Gynecologic Oncology Journal Club: The ABCs of ADCs (Antibody drug Conjugates) - https://bit.ly/42U2962 Antibody-Drug Conjugates in Gynecologic Cancers - https://bit.ly/4cLYECZ Funder Statement This program is supported by AbbVie.
We kicked off the program with four news stories and different guests on the stories we think you need to know about!Survey: 53% of Consumers Don't Know What a FICO Score Is! Adriana Ocanas - consumer credit cards analyst at U.S. News & World Report joined Dan to discuss!Susan Shapiro -gender expert and bestselling author of "Estranged: How Strained Female Friendships are Mended or Ended." The complexities of female friendships and how they differ than male relationships. Lowell General Hospital's TeamWalk for Cancer Care is coming up on Sunday, May 4th! Bruce Robinson - Board of trustees Development Chair, Lowell General Hospital stopped by.CDC weighing end to universal COVID vaccine recommendations. Dr. Shira Doron - Chief Infection Control Officer for Tufts Medicine and Hospital Epidemiologist at Tufts Medical Center checked in.Listen to WBZ NewsRadio on the NEW iHeart Radio app and be sure to set WBZ NewsRadio as your #1 preset!
This week we bring together urologists and radiologists to work towards a shared goal of innovating on kidney cancer care. Dr. Jason Abel, Professor of Urology and Radiology at the University of Wisconsin, and Dr. Louis Hinshaw, Section Chief of Abdominal Imaging Intervention at the University of Wisconsin, join our host Dr. Ruchika Talwar for a multidisciplinary conversation regarding the treatment of renal tumors. --- SYNPOSIS Their discussion covers the history and benefits of collaboration between urology and interventional radiology (IR), advances in image-guided procedural technologies, and the importance of teamwork in improving patient outcomes. The episode also considers the encouraging, but limited data in IR treatments such as microwave ablation and discusses the lasting role for surgery. Finally, Dr. Abel and Dr. Hinshaw share their experiences in establishing a successful interdisciplinary kidney cancer program. Ultimately, they conclude that the future of renal tumor treatment lies not in silos, but in collaboration. --- TIMESTAMPS 00:00 - Introduction 04:04 - Collaboration Between Urologists and Interventional Radiologists 05:58 - Advancements in Ablation 10:05 - Patient Selection 15:19 - Technical Considerations 26:57 - Post-Ablation Surveillance and Recurrence Management 33:19 - Conclusion
This week we bring together urologists and radiologists to work towards a shared goal of innovating on kidney cancer care. Dr. Jason Abel, Professor of Urology and Radiology at the University of Wisconsin, and Dr. Louis Hinshaw, Section Chief of Abdominal Imaging Intervention at the University of Wisconsin, join our host Dr. Ruchika Talwar for a multidisciplinary conversation regarding the treatment of renal tumors. --- SYNPOSIS Their discussion covers the history and benefits of collaboration between urology and interventional radiology (IR), advances in image-guided procedural technologies, and the importance of teamwork in improving patient outcomes. The episode also considers the encouraging, but limited data in IR treatments such as microwave ablation and discusses the lasting role for surgery. Finally, Dr. Abel and Dr. Hinshaw share their experiences in establishing a successful interdisciplinary kidney cancer program. Ultimately, they conclude that the future of renal tumor treatment lies not in silos, but in collaboration. --- TIMESTAMPS 00:00 - Introduction 04:04 - Collaboration Between Urologists and Interventional Radiologists 05:58 - Advancements in Ablation 10:05 - Patient Selection 15:19 - Technical Considerations 26:57 - Post-Ablation Surveillance and Recurrence Management 33:19 - Conclusion
Send us a textCalifornia stands as one of only five states without proper massage therapy licensing, operating instead under a questionable "voluntary certification" system run by the California Massage Therapy Council (CAMTC). This system charges therapists $300 every two years for a certification that requires minimal education, no continuing education, and no examination, while creating barriers for therapist mobility and failing to protect the public.• CAMTC is a private, non-profit corporation that has been criticized for lack of transparency and accountability• The CEO of CAMTC reportedly earns over half a million dollars while the organization collects $8 million in fees• CAMTC has arbitrarily denied certificates to qualified students and operates without due process requirements• California therapists face significant barriers when attempting to practice in other states• Professional organizations including AMTA and ABMP support sunsetting CAMTC• A hearing on April 29th could determine whether CAMTC will be dissolvedShow notes:----> ABMP Template for Writing a Letter to California Legislators
How should BC improve its rural cancer care? Guest: Cyndi Logan, Myeloma Patient from Quesnel Learn more about your ad choices. Visit megaphone.fm/adchoices
In this episode of 'Speak the Truth,' listeners are invited to register for the upcoming ABC Call to Council conference. Mike is joined with Justin Greene and Mary Young, both cancer survivors, discuss their newly launched Cancer Care Ministry at Salem Heights Church. They share their personal journeys with cancer, the unique challenges faced by cancer patients, and how the new ministry aims to provide practical support, emotional comfort, and spiritual guidance. Key topics include the importance of humor, sharing stories, and maintaining hope amid suffering. Additionally, they emphasize the necessity for other churches to consider establishing similar support groups and provide resources for starting such initiatives. 00:00 Introduction and Conference Announcement01:39 Welcome to Speak the Truth Podcast02:13 Introducing Justin Green and Mary Young02:37 Justin's Cancer Journey04:48 Mary's Cancer Journey06:15 Launching the Cancer Care Ministry16:33 The Oasis Cancer Support Groups27:39 Encouragement and Resources for Churches30:17 Conclusion and Contact InformationEpisode MentionsOur Journey of Hope - Cancer Resources
Raising awareness about disparities in cancers impacting women, screening among Indigenous populations, and barriers to accessing care is essential. The Association of Cancer Care Centers (ACCC) is dedicating to providing up-to-date information on approaches to improving women's health screening, education, and prevention in Indigenous subpopulations. In this episode, CANCER BUZZ speaks with Tricia Numan, MD, assistant professor of pathology at Roswell Park Comprehensive Cancer Center about geographical challenges to accessing care and strategies for culturally tailored approaches for indigenous women. “[There] are some major things that have happened in not so recent past to native populations, and I think it's really important for health care providers to take that recent history into account when they're caring for native patients.” – Tricia Numan, MD “If you want to culturally tailor your health care I think that it's very important, because it's not a one size fits all.” Tricia Numan, MD Gynecologic Pathologist Assistant Professor of Pathology Department of Pathology & Laboratory Medicine Department of Indigenous Cancer Health Roswell Park Comprehensive Cancer Center Buffalo, New York Resources: Roswell Park Department of Indigenous Cancer Health Oncology Issues Roswell Park Article
From initial symptoms to survivorship, understanding bone cancer care is crucial for primary care providers. During this episode of Banner Health's Making the Rounds podcast, we'll explore the complexities of bone cancer diagnoses, treatment pathways and the vital role of primary care providers in supporting patients across every stage of their journey. We'll cover the different types of bone cancer, the importance of a multidisciplinary approach and how primary care can bridge the gap between oncology specialists and families facing this difficult diagnosis.You'll hear from Dr. Ahmed Elabd, an orthopedic oncology specialist at Banner - University Medicine Tucson and the University of Arizona Cancer Center, and assistant professor of orthopedics at the University of Arizona College of Medicine - Tucson. Dr. Elabd is a specialist in treating both pediatric and adult patients with bone cancer.
On the inaugural episode of ASCO Education: By the Book, Dr. Nathan Pennell and Dr. Don Dizon share reflections on the evolution of the ASCO Educational Book, its global reach, and the role of its new companion podcast to further shine a spotlight on the issues shaping the future of modern oncology. TRANSCRIPT Dr. Nathan Pennell: Hello, I'm Dr. Nate Pennell, welcoming you to the first episode of our new podcast, ASCO Education: By the Book. The podcast will feature engaging discussions between editors and authors from the ASCO Educational Book. Each month, you'll hear nuanced views on key topics in oncology featured in Education Sessions at ASCO meetings, as well as some deep dives on the advances shaping modern oncology. Although I am honored to serve as the editor-in-chief (EIC) of the ASCO Educational Book, in my day job, I am the co-director of the Cleveland Clinic Lung Cancer Program and vice chair for clinical research for the Taussig Cancer Center here in Cleveland. I'm delighted to kick off our new podcast with a discussion featuring the Ed Book's previous editor-in-chief. Dr. Don Dizon is a professor of medicine and surgery at Brown University and works as a medical oncologist specializing in breast and pelvic malignancies at Lifespan Cancer Institute in Rhode Island. Dr. Dizon also serves as the vice chair for membership and accrual at the SWOG Cancer Research Network. Don, it's great to have you here for our first episode of ASCO Education: By the Book. Dr. Don Dizon: Really nice to be here and to see you again, my friend. Dr. Nathan Pennell: This was the first thing I thought of when we were kicking off a podcast that I thought we would set the stage for our hopefully many, many listeners to learn a little bit about what the Ed Book used to be like, how it has evolved over the last 14 years or so since we both started here and where it's going. You started as editor-in-chief in 2012, is that right? Dr. Don Dizon: Oh, boy. I believe that is correct, yes. I did two 5-year stints as EIC of the Educational Book, so that sounds about right. Although you're aging me very clearly on this podcast. Dr. Nathan Pennell: I had to go back in my emails to see if I could figure out when we started on this because we've been working on it for some time. Start out a little bit by telling me what do you remember about the Ed Book from back in the day when you were applying to be editor-in-chief and thinking about the Ed Book. What was it like at that time? Dr. Don Dizon: You know, it's so interesting to think about it. Ten years ago, we were both in a very different place in our careers, and I remember when the Ed Book position came up, I had been writing a column for ASCO. I had done some editorial activities with other journals for sure, but what always struck me was it was very unclear how one was chosen to be a part of the education program at ASCO. And then it was very unclear how those faculty were then selected to write a paper for the Educational Book. And it was back in the day when the Educational Book was completely printed. So, there was this book that was cherished among American fellows in oncology. And it was one that, when I was newly attending, and certainly two or three years before the editor's position came up, it was one that I referenced all the time. So, it was a known commodity for many of us. And there was a certain sense of selectivity about who was invited to write in it. And it wasn't terribly transparent either. So, when the opportunity to apply for editor-in-chief of the Educational Book came up, I had already been doing so much work for ASCO. I had been on the planning committees and served in many roles across the organization, and editing was something I found I enjoyed in other work. So, I decided to put my name in the ring with the intention of sort of bringing the book forward, getting it indexed, for example, so that there was this credit that was more than just societal credit at ASCO. This ended up being something that was referenced and acknowledged as an important paper through PubMed indexing. And then also to provide it as a space where we could be more transparent about who was being invited and broadening the tent as to who could participate as an author in the Ed Book. Dr. Nathan Pennell: It's going to be surprising to many of our younger listeners to learn that the Educational Book used to be just this giant, almost like a brick. I mean, it was this huge tome of articles from the Education Sessions that you got when you got your meeting abstracts book at the annual meeting. And you can always see people on the plane on the way out of Chicago with their giant books. Dr. Don Dizon: Yes. Dr. Nathan Pennell: That added lots of additional weight to the plane, I'm sure, on the way out. Dr. Don Dizon: And it was not uncommon for us to be sitting at an airport, and people would be reading those books with highlighters. Dr. Nathan Pennell: I fondly remember being a fellow and coming up and the Ed Book was always really important to me, so I was excited. We'll also let the listeners in on that. I also applied to be the original editor-in-chief of the Ed Book back in 2012, although I was very junior and did not have any real editorial experience. I think I may have been section editor for The Oncologist at that point. And I had spoken to Dr. Ramaswamy Govindan at WashU who had been the previous editor-in-chief about applying and he was like, “Oh yeah. You should absolutely try that out.” And then when Dr. Dizon was chosen, I was like, “Oh, well. I guess I didn't get it.” And then out of the blue I got a call asking me to join as the associate editor, which I was really always very thankful for that opportunity. Dr. Don Dizon: Well, it was a highly fruitful collaboration, I think, between you and I when we first started. I do remember taking on the reins and sort of saying, “You know, this is our vision of what we want to do.” But then just working with the authors, which we did, about how to construct their papers and what we were looking for, all of that is something I look back really fondly on. Dr. Nathan Pennell: I think it was interesting too because neither one of us had really a lot of transparency into how things worked when we started. We kind of made it up a little bit as we went along. We wanted to get all of the faculty, or at least as many of them as possible contributing to these. And we would go to the ASCO Education Committee meeting and kind of talk about the Ed Book, and we were thinking about, you know, how could we get people to submit. So, at the time it wasn't PubMed indexed. Most people, I think, submitted individual manuscripts just from their talk, which could be anywhere from full length review articles to very brief manuscripts. Dr. Don Dizon: Sometimes it was their slides with like a couple of comments on it. Dr. Nathan Pennell: And some of them were almost like a summary of the talk. Yeah, exactly. And so sort of making that a little more uniform. There was originally an honorarium attached, which went away, but I think PubMed indexing was probably the biggest incentive for people to join. I remember that was one of the first things you really wanted to get. Dr. Don Dizon Yeah. And, you know, it was fortuitous. I'd like to take all the credit for it, but ASCO was very forward thinking with Dr. Ramaswamy and the conversations about going to PubMed with this had preceded my coming in. We knew what we needed to do to get this acknowledged, which was really strengthening the peer review so that these papers could meet the bar to get on PubMed. But you know, within the first, what, two or three years, Nate, of us doing this, we were able to get this accepted. And now it is. If you look at what PubMed did for us, it not only increased the potential of who was going to access it, but for, I think the oncology community, it allowed people access to papers by key opinion leaders that was not blocked by a paywall. And I thought that was just super important at the time. Social media was something, but it wasn't what it is now. But anybody could access these manuscripts and it's still the case today. Dr. Nathan Pennell: I think it's hard to overstate how important that was. People don't realize this, but the Ed Book is really widely accessed, especially outside the US as well. And a lot of people who can't attend the meeting to get the print, well, the once print, book could actually get access to essentially the education session from the annual meeting without having to fly all the way to the US to attend. Now, you know, we have much better virtual meeting offerings now and whatnot. But at the time it was pretty revolutionary to be able to do that. Dr. Don Dizon: Yeah, and you know, it's so interesting when I think back to, you know, this sort of evolution to a fully online publication of the Ed Book. It was really some requests from international participants of the annual meeting who really wanted to continue to see this in print. At that time, it was important to recognize that access to information was not uniform across the world. And people really wanted that print edition, maybe not for themselves, but so that access in more rural areas or where access in the broadband networks were not established that they still could access the book. I think things have changed now. We were able, I think, in your tenure, to see it fully go online. But even I just remember that being a concern as we went forward. Dr. Nathan Pennell: Yeah, we continued with the print book that was available if people asked for it, but apparently few enough people asked for it that it moved fully online. One of the major advantages of being fully online now is of course, it does allow us to publish kind of in real time as the manuscripts come out in the months leading up to the meeting, which has been, I think, a huge boon because it can build momentum for the Education Sessions coming in. People, you know, really look forward to it. Dr. Don Dizon: Yeah, that was actually a concern, you know, when we were phasing out Ed Book and going to this continuous publication model where authors actually had the ability to sort of revise their manuscript and that would be automatically uploaded. You had a static manuscript that was fully printed, and it was no longer an accurate one. And we did have the ability to fix it. And it just goes to show exactly what you're saying. This idea that these are living papers was really an important thing that ASCO embraced quite early, I think. Dr. Nathan Pennell: And with the onset of PubMed indexing, the participation from faculty skyrocketed and almost within a couple of years was up to the vast majority of sessions and faculty participating. Now I think people really understand that this is part of the whole process. But at the time I remember writing out on my slides in all caps, “THIS IS AN EXPECTATION.” And that's about the best word I could give because I asked if we could make people do it, and they were like, no, you can't make people do it. Dr. Don Dizon: So right. Actually, I don't think people are aware of the work on the back end every year when I was on as EIC, Nate and myself, and then subsequently Dr. Hope Rugo would have these informational sessions with the education faculty and we would tout the Ed Book, tout the expectation, tout it was PubMed indexed and tout multidisciplinary participation. So, we were not seeing four manuscripts reflecting one session. You know, this encouragement to really embrace multidisciplinary care was something that very early on we introduced and really encouraged people not to submit perspective manuscripts, but to really get them in and then harmonize the paper so that it felt like it was, you know, one voice. Dr. Nathan Pennell: I consider that after PubMed indexing, the next major change to the Ed Book, that really made it a better product and that was moving from, you know, just these short individual single author manuscripts to single session combined manuscript that had multiple perspectives and topics, really much more comprehensive review articles. And I don't even remember what the impetus was for that, but it was really a success. Dr. Don Dizon: Yeah, I mean, I think in the beginning it was more of a challenge, I think, because people were really not given guidance on what these papers were supposed to look like. So, we were seeing individual manuscripts come forward. Looking back, it really foreshadowed the importance of multidisciplinary management. But at the time, it was really more about ensuring that people were leaving the session with a singular message of what to do when you're in clinic again. And the goal was to have the manuscripts reflect that sort of consensus view of a topic that was coming in. There were certain things that people still argued would not fit in a multidisciplinary manuscript. You know, if you have someone who's writing and whose entire talk was on the pathology of thyroid cancer. Another topic was on survivorship after thyroid cancer. It was hard to sort of get those two to interact and cover what was being covered. So, we were still getting that. But you're right, at the end of my tenure and into yours, there were far fewer of those individual manuscripts. Dr. Nathan Pennell: And I think it's even made it easier to write because now, you know, you just have to write a section of a manuscript and not put together an entire review. So, it has helped with getting people on board. Dr. Don Dizon: Well, the other thing I thought was really interesting about the process is when you're invited to do an Education Session at ASCO, you're either invited as a faculty speaker or as the chair of the session. And the responsibility of the chair is to ensure that it flows well and that the talks are succinct based on what the agenda or the objectives were as defined by the education committee for that specific group. But that was it. So really being named “Chair” was sort of an honor, an honorific. It really didn't come with responsibility. So, we use the Ed Book as a way to say, “As chair of the session, it is your responsibility to ensure A, a manuscript comes to me, but B, that the content of that paper harmonizes and is accurate.” And it was very rare, but Nate, I think we got dragged into a couple of times where the accuracy of the manuscript was really called into question by the chair. And those were always very, very tricky discussions because everyone that gets invited to ASCO is a recognized leader in their field. Some of us, especially, I would probably say, dating back 10 years from today, the data behind Standards of Care were not necessarily evidence-based. So, there were a lot of opinion-based therapies. You know, maybe not so much in the medical side, but certainly some of it. But when you went to, you know, surgical treatments and maybe even radiotherapy treatments, it was really based on, “My experience at my center is this and this is why I do what I do.” But those kinds of things ended up being some of the more challenging things to handle as an editor. Dr. Nathan Pennell: And those are the– I'll use “fun” in a broad sense. You know, every once in a while, you get an article where it really does take a lot of hands-on work from the editor to work with the author to try to revise it and make it a suitable academic manuscript. But you know what? I can't think, at least in recent years, of any manuscripts that we turned down. They just sometimes needed a little TLC. Dr. Don Dizon: Yeah. And I think the other important thing it reminds me of is how great it was that I wasn't doing this by myself. Because it was so great to be able to reach out to you and say, “Can you give me your take on this paper?” Or, “Can you help me just join a conference call with the authors to make sure that we're on the same page?” And then on the rare example where we were going to reject a paper, it was really important that we, as the editorial team, and I include our ASCO shepherder, through the whole process. We had to all agree that this was not salvageable. Fortunately, it happened very rarely. But I've got to say, not doing this job alone was one of the more important facets of being the EIC of ASCO's Educational Book. Dr. Nathan Pennell: Well, it's nice to hear you say that. I definitely felt that this was a partnership, you know, it was a labor of love. So, I want to go to what I consider sort of the third major pillar of the changes to the Ed Book during your tenure, and that was the introduction of a whole new kind of manuscript. So up to, I don't know, maybe seven or eight years ago, all the articles were authored just by people who were presenting at the Annual Meeting. And then you had an idea to introduce invited manuscripts. So take me through that. Dr. Don Dizon: Yeah, well, you know, again, it went to this sort of, what can people who are being asked to sort of lead ASCO for that year, what can they demonstrate as sort of a more tangible contribution to the Society and to oncology in general? And I think that was the impetus to use the Ed Book for everyone who was in a leadership position to make their mark. That said, I was here, and I was either president of the society or I was Education Program Chair or Scientific Program Chair, and they got to select an article type that was not being covered in the annual meeting and suggest the authors and work with those authors to construct a manuscript. Never did any one of those folks suggest themselves, which I thought was fascinating. They didn't say, “I want to be the one to write this piece,” because this was never meant to be a presidential speech or a commemorative speech or opportunity for them as leaders. But we wanted to ensure that whatever passion they had within oncology was represented in the book. And again, it was this sort of sense of, I want everyone to look at the Ed Book and see themselves in it and see what they contributed. And that was really important for those who were really shepherding each Annual Meeting each year for ASCO that they had the opportunity to do that. And I was really pleased that leadership really took to that idea and were very excited about bringing ideas and also author groups into the Educational Book who would not have had the opportunity otherwise. I thought that was just really nice. It was about inclusiveness and just making sure that people had the opportunity to say, “If you want to participate, we want you to participate.” Dr. Nathan Pennell: Yeah, I agree. I think the ASCO leadership jumped on this and continues to still really appreciate the opportunity to be able to kind of invite someone on a topic that's meaningful to them. I think we've tried to work in things that incorporate the presidential theme each year in our invited manuscript, so it really allows them to put kind of a stamp on the flavor of each edition. And the numbers reflect that these tend to be among our more highly read articles as well. Dr. Don Dizon: You know, looking back on what we did together, that was something I'm really, really quite proud of, that we were able to sort of help the Educational Book evolve that way. Dr. Nathan Pennell: I agree. You brought up briefly a few minutes ago about social media and its role over time. I think when we started in 2012, I had just joined Twitter now X in 2011, and I think we were both sort of early adopters in the social media. Do you feel like social media has had a role in the growth of the Ed Book or is this something that you think we can develop further? Dr. Don Dizon: When we were doing Ed Book together, professional social media was actually a quite identified space. You know, we were all on the same platform. We analyzed what the outcomes were on that platform and our communities gathered on that platform. So, it was a really good place to highlight what we were publishing, especially as we went to continuous publishing. I don't remember if it was you or me, but we even started asking our authors for a tweet and those tweets needed work. It was you. It was you or I would actually lay in these tweets to say, “Yeah, we need to just, you know, work on this.” But I think it's harder today. There's no one preferred platform. Alternate platforms are still evolving. So, I think there are opportunities there. The question is: Is that opportunity meaningful enough for the Ed Book to demonstrate its return on an investment, for example? What I always thought about social media, and it's still true today, is that it will get eyes on whatever you're looking at far beyond who you intended to see it. So, you know, your tweets regarding a phase 3 clinical trial in lung cancer, which were so informative, were reaching me, who was not a lung oncologist who doesn't even see lung cancer and getting me more interested in finding that article and more and more pointing to the Educational Book content that speaks to that piece, you know. And I think coupling an impression of the data, associating that with something that is freely accessed is, I think, a golden opportunity not only for our colleagues, but also for anyone who's interested in a topic. Whether you are diagnosed with that cancer or you are taking care of someone with that cancer, or you heard about that cancer, there are people who would like to see information that is relevant and embedded and delivered by people who know what they're talking about. And I think our voices on social media are important because of it. And I think that's where the contribution is. So, if we had to see what the metric was for any social media efforts, it has to be more of the click rates, not just by ASCO members, but the click rates across societies and across countries. Dr. Nathan Pennell: Yeah, social media is, I mean, obviously evolving quite a bit in the last couple of years. But I do know that in terms the alt metrics for the track access through social media and online, the ones that are shared online by the authors, by the Ed Book team, do seem to get more attention. I think a lot of people don't like to just sit with a print journal anymore or an email table of contents for specific journals. People find these articles that are meaningful to them through their network and oftentimes that is online on social media. Dr. Don Dizon: Yes, 100%. And you know what I think we should encourage people to do is look at the source. And if the Ed Book becomes a source of information, I think that will be a plus to the conversations in our world. We're still dealing with a place where, depending on who sponsored the trial, whether it was an industry-sponsored trial, whether it was NCI sponsored or sponsored by the National Institutes of Health, for example, access to the primary data sets may or may not be available across the world, but the Ed Book is. And if the Ed Book can summarize that data and use terms and words that are accessible no matter what your grade level of education is. If we can explain the graphs and the figures in a way that people can actually easily more understand it. If there's a way that we structure our conversations in the Ed Book so that the plethora of inclusion/exclusion criteria are summarized and simplified, then I think we can achieve a place where good information becomes more accessible, and we can point to a summary of the source data in places where the source is not available. Dr. Nathan Pennell: One of the other things that I continue to be surprised at how popular these podcasts are. And that gives you an opportunity pretty much the opposite. Instead of sort of a nugget that directs you to the source material, you've got a more in-depth discussion of the manuscript. And so, I'm delighted that we have our own podcast. For many years, the Ed Book would sort of do a sort of a “Weird Al takeover” of the ASCO Daily News Podcast for a couple of episodes around the Annual Meeting, and I think those were always really popular enough that we were able to argue that we deserved our own podcast. And I'm really looking forward to having these in-depth discussions with authors. Dr. Don Dizon: It's an amazing evolution of where the Ed Book has gone, right? We took it from print only, societally only, to something that is now accessed worldwide via PubMed. We took it from book to fully online print. And now I think making the content live is a natural next step. So, I applaud you for doing the podcast and giving people an opportunity actually to discuss what their article discusses. And if there's a controversial point, giving them the freedom and the opportunity to sort of give more nuanced views on what may not be something that there's 100% consensus over. Dr. Nathan Pennell: Yes. Well, I hope other people enjoy these as well. Just want to highlight a few of the things that have happened just in the couple years since you stepped down as editor-in-chief. One of them, and I don't know if you noticed, but last year we started adding manuscripts from the ASCO thematic meetings, so ASCO GI and ASCO GU, something we had certainly talked about in the past, but had lacked bandwidth to really do. And they seem to be pretty widely accessed. Dr. Don Dizon: That's fantastic. Yes, I do remember talking about the coverage of the thematic meetings and you're right, this takes a long time to sort of concentrate on the Annual Meeting. It may seem like everything happens in the span of like eight weeks. Dr. Nathan Pennell: It does feel like that sometimes. Dr. Don Dizon: Right? But this is actually something that starts a year before, once the education program is set. We're in the room when they set it. But then it's really chasing down manuscripts and then making sure that they're peer reviewed because the peer review is still really important, and then making sure that any revisions are made before it's finalized and goes to press. That is a many months process. So, when we're trying to introduce, “Oh, we should also do ASCO GU or-,” the question was, how do you want to do that given this very, very involved process going forward? So, I'm glad you were able to figure it out. Dr. Nathan Pennell: Well, it's challenging. I don't think people realize quite the compressed timeline for these. You know, the Education Session and authors and invited faculty are picked in the fall, and then basically you have to start turning in your manuscripts in February, March of the following year. And so, it's a really tight turnaround for this. When we talk about the ASCO thematic meetings, it's an even tighter window. Dr. Don Dizon: Right, exactly. Dr. Nathan Pennell: And so, it's challenging to get that moving, but I was really, really proud that we were able to pull that off. Dr. Don Dizon: Well, congratulations again. And I think that is a necessary step, because so much of what's going on in the various disease management sites is only covered cursorily through the Annual Meeting itself. I mean, there's just so much science breaking at any one time that I think if we want to comprehensively catalog the Year in Review in oncology, it kind of behooves us to do that. Dr. Nathan Pennell: Some other things that are coming up because we now have manuscripts that are going to be coming in year-round, and just to kind of make it easier on the editorial staff, we're going to be forming an editorial board. And in addition to our pool of reviewers who get ASCO points, please feel free to go online to the ASCO volunteer portal and sign up if you are interested in participating. So, moving forward, I'm really excited to see where things are going to go. Dr. Don Dizon: Well, that's great. That's great. And I do remember talking about whether or not we needed to have an editorial board. At least when I was there, having this carried by three people was always better than having it carried by one person. And I think as you expand the potential for submissions, it will be very helpful to have that input for sure. And then it gives another opportunity for more members to get involved in ASCO as well. Dr. Nathan Pennell: Absolutely. People want involvement, and so happy to provide that. Dr. Don Dizon: Yes. Dr. Nathan Pennell: Is there anything we didn't cover that you would like to mention before we wrap up? Dr. Don Dizon: Well, I will say this, that ASCO and through its publications not only has had this real emphasis on multidisciplinary management of cancers, especially where it was relevant, but it also always had a stand to ensure representation was front and center and who wrote for us. And I think every president, every chair that I've worked with naturally embraced that idea of representation. And I think it has been a distinct honor to say that during my tenure as EIC, we have always had a plethora of voices, of authors from different countries, of genders, that have participated in the construction of those books. And it stands as a testament that we are a global community and we will always be one. Dr. Nathan Pennell: Well, thank you for that. And I'm happy to continue that as we move forward. Well, Don, thank you. It's been great speaking with you. You played such a pivotal role in the Ed Book's evolution and I'm so glad you were able to join me for our inaugural episode. Dr. Don Dizon: Well, I'm just tickled that you asked me to be your first guest. Thank you so much, Nate. Dr. Nathan Pennell: And I also want to thank our listeners for joining us today. We hope you'll join us again for more insightful views on topics you'll be hearing at the Education Sessions from ASCO meetings throughout the year, as well as our periodic deep dives on advances that are shaping modern oncology. Have a great day. Disclaimer: The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity or therapy should not be construed as an ASCO endorsement. Follow today's speakers: Dr. Nathan Pennell @n8pennell @n8pennell.bsky.social Dr. Don Dizon @drdondizon.bsky.social Follow ASCO on social media: @ASCO on X (formerly Twitter) ASCO on Bluesky ASCO on Facebook ASCO on LinkedIn Disclosures: Dr. Nathan Pennell: Consulting or Advisory Role: AstraZeneca, Lilly, Cota Healthcare, Merck, Bristol-Myers Squibb, Genentech, Amgen, G1 Therapeutics, Pfizer, Boehringer Ingelheim, Viosera, Xencor, Mirati Therapeutics, Janssen Oncology, Sanofi/Regeneron Research Funding (Inst): Genentech, AstraZeneca, Merck, Loxo, Altor BioScience, Spectrum Pharmaceuticals, Bristol-Myers Squibb, Jounce Therapeutics, Mirati Therapeutics, Heat Biologics, WindMIL, Sanofi Dr. Don Dizon: Stock and Other Ownership Interests: Midi, Doximity Honoraria: UpToDate, American Cancer Society Consulting or Advisory Role: AstraZeneca, Clovis Oncology, Kronos Bio, Immunogen Research Funding (Institution): Bristol-Myers Squibb
What if a medical specialty society could drive groundbreaking research, fuel a global movement, and train the next generation of clinical investigators—all while tripling its membership in just five years? In a world of rapidly evolving cancer care, how can associations champion new modalities and build a community around transformative treatment approaches? In this episode of Associations Thrive, host Joanna Pineda interviews Jena Stack, Executive Director of the Society of Interventional Oncology (SIO). Jena discusses:How interventional oncology is emerging as the fourth pillar of cancer care, alongside surgery, chemotherapy, and radiation.How interventional oncologists use minimally invasive, image-guided techniques to target cancer with fewer side effects and faster recovery.How SIO has tripled in membership since 2020, growing from a small niche society to nearly 1,500 members globally.SIO's impressive governance model, which prioritizes relationship-building and alignment between the board and staff.How SIO is leading its own multi-million dollar clinical trials to address gaps in evidence and influence standards of care. Typically, this role has been reserved for pharma companies or academic institutions.The creation of the Clinical Trial Collaborative (CTC), a new research community and certificate program that trains and connects principal investigators.SIO's long-term vision to empower more physicians to lead studies and expand access to minimally invasive cancer treatments.The importance of "pausing to retreat" during growth, and how SIO balances ambition with sustainability.References:SIO Website
In this inspiring episode, I sit down with Rachel Frankenthal, a board-certified Physician Assistant and Menopause Society Certified Practitioner, whose work is transforming the lives of cancer survivors. Rachel specialises in gynaecological oncology at UCLA, supporting women through both cancer treatment and survivorship—particularly those navigating treatment-induced menopause.But Rachel's story is anything but ordinary! From her early days as a Broadway performer to becoming a leading voice in survivorship care, she shares how her journey shaped her passion for holistic, patient-centred healthcare. She has played a pivotal role in developing UCLA's Gynaecologic Cancer Survivorship Program and started a dedicated menopause clinic to support survivors in reclaiming their well-being.Join us as we discuss the power of integrative care, movement, and mindfulness, and how Rachel is changing the future of menopause support for cancer survivors. This conversation is full of wisdom, hope, and a reminder that the right care can change lives.Episode Highlights:00:00 Intro05:27 Rachel's Yoga Journey13:07 Comprehensive Patient Follow-Up Visits16:51 Post-Treatment Confusion and Anxiety20:15 Embracing a Healthcare Paradigm Shift23:13 Menopausal Symptoms in Cancer Survivors24:30 "Advocating Awareness in Cancer Care"29:09 Empowering Mid-Level Providers in Oncology31:42 Yoga Program Reduces Treatment Side Effects35:35 Community Healing Through Connection38:17 Normalising Post-Cancer Intimacy ChallengesFind Rachel here https://www.instagram.com/rachelfrankenthal/ Attached are resources: The British Gyn Cancer Society Guidelines https://thebms.org.uk/publications/bms-guidelines/management-of-menopausal-symptoms-following-treatment-of-gynaecological-cancer/- Here's the link to Rachel's course "Hormone Therapy for Gyn Cancer Survivors": https://heatherhirschacademy.com/course/managing-hormone-therapy-for-gynecologic-cancer-survivors/Connect with us:For more information and resources visit our website: www.menopauseandcancer.org Or follow us on Instagram @menopause_and_cancerJoin our Facebook group: www.facebook.com/groups/menopauseandcancerchathub
In this episode of the Bench to Bedside podcast, Dr. Roy Jensen, vice chancellor and director of The University of Kansas Cancer Center, is joined by Dr. Lisa Harlan-Williams, associate director for education at the cancer center, to discuss the variety of careers involved in the field of cancer care and research, beyond doctors and nurses. Dr. Harlan-Williams shares her own career path and talks about various initiatives at KU Cancer Center to attract and train for the oncology workforce. They highlight the importance of early exposure to different career opportunities and the educational programs available, including shadowing professionals and summer research internships. The discussion also touches on the growing demand for cancer care professionals due to increasing cancer cases and workforce shortages. Do you have questions about cancer? Call our Bench to Bedside Hotline at (913) 588-3880 or email us at benchtobedside@kumc.edu, and your comment or question may be shared on an upcoming episode! If you appreciated this episode, please share, rate, subscribe and leave a review. To ensure you get our latest updates, For the latest updates, follow us on the social media channel of your choice by searching for KU Cancer Center. Links from this Episode: Learn more about educational opportunities and programs for students considering a career in cancer research at KU Cancer Center Learn about the Accelerate Cancer Education summer research program at KU Cancer Center Read about the C-CLEAR summer internship program at KU Cancer Center Learn more about the Jewell Summer Research Training Program at KU Cancer Center
In this episode, we dive into the transformative power of art therapy in cancer care. Art therapy goes beyond traditional treatment by offering patients a creative outlet to express their emotions, manage stress, and find relaxation during their journey. Emphasizing the process over perfection, art therapy creates a safe, supportive space for individuals to explore their creativity and enhance their emotional well-being. Whether through painting, drawing, or other forms of expression, patients are encouraged to engage in art as a tool for healing and connection.About Our Guest:We are joined by Lisa Shea, MA, ATR-BC. Lisa holds a Bachelor of Fine Arts from Miami University and a Master's in Art Therapy from Wright State University. With a diverse background in psychiatric hospitals, community mental health centers, and schools, Lisa has made a profound impact on her patients' lives. In 2012, she became the first full-time art therapist at the Cleveland Clinic's Taussig Cancer Center, where she's played a crucial role in bringing the healing power of art to cancer patients.Tune in to hear how art therapy is reshaping the patient experience and offering a new path to emotional wellness during the challenging journey of cancer care.
The Real Truth About Health Free 17 Day Live Online Conference Podcast
Karla Mans Giroux delves into the research on radical remission and how lifestyle choices can help overcome cancer. Discover powerful strategies and stories of hope that highlight the impact of holistic living on cancer recovery. #RadicalRemission #LifestyleChoices #CancerRecovery
The Real Truth About Health Free 17 Day Live Online Conference Podcast
Join Dr. Henning Saupe as he explores non-toxic, gentle methods to treat cancer effectively. Learn about alternative therapies that support healing without the harsh side effects of traditional treatments. Discover a holistic approach to cancer care. #NonToxicTreatment #CancerHealing #HolisticHealth
CancerNetwork® visited Sibley Memorial Hospital of Johns Hopkins Medicine to speak with a variety of experts about therapeutic advancements and ongoing research initiatives across several different cancer fields. As part of each discussion, clinicians highlighted how collaboration across different departments has positively impacted treatment planning, decision-making, and outcomes at their institution. These experts included the following: · Rachit Kumar, MD, an assistant professor of Radiation Oncology and Molecular Radiation Sciences at Johns Hopkins School of Medicine and a radiation oncologist specializing in genitourinary and gastrointestinal cancers at Johns Hopkins Sidney Kimmel Comprehensive Cancer Center for Sibley Memorial Hospital and Suburban Hospital; · Michael J. Pishvaian, MD, PhD, director of Gastrointestinal, Developmental Therapeutics, and Clinical Research Programs, and associate professor of Oncology at Johns Hopkins School of Medicine; · Nina Wagner-Johnston, MD, a professor of Oncology and the director of Lymphoma Drug Development at the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University, director of Hematologic Malignancies National Capital Region, and co-director of Clinical Research for Hematologic Malignancies; · Valerie Lee, MD, an assistant professor of Oncology at Johns Hopkins University School of Medicine and a medical oncologist at Johns Hopkins Sidney Kimmel Comprehensive Cancer Center at Sibley Memorial Hospital; · Armine Smith, MD, the director of urologic oncology at the Sidney Kimmel Comprehensive Cancer Center at Sibley Memorial Hospital, and an assistant clinical professor of Urology at the Brady Urological Institute of Johns Hopkins University School of Medicine; · Pouneh Razavi, MD, the director for Breast Imaging in the National Capital Region and an instructor in Radiology and Radiological Science; · and Curtiland Deville Jr., MD, medical director of the Johns Hopkins Proton Therapy Center and clinical director of Radiation Oncology at Johns Hopkins Sidney Kimmel Comprehensive Cancer Center at Sibley Memorial Hospital. Altogether, their insights demonstrated how multidisciplinary teamwork has improved outcomes ranging from patient survival to healthcare resource utilization across a wide range of diseases including breast cancer, gastrointestinal cancer, genitourinary cancer, hematologic malignancies, and others.
In this episode of “Answers From the Lab,” William Morice II, M.D., Ph.D., CEO and president of Mayo Clinic Laboratories, invited Min-Han Tan, M.B.B.S., FRCP, Ph.D., founding CEO and medical director of Lucence, to discuss liquid biopsy cancer testing. Mayo Clinic Laboratories and Lucence recently announced a collaboration to expand access to this cutting-edge cancer test that is designed to detect clinically relevant biomarkers in ctDNA and ctRNA.During their conversation, Dr. Morice and Dr. Tan explore:Inspiration for developing the liquid biopsy.Features that differentiate LiquidHALLMARK® from existing cancer tests.Patients who will benefit from the test and how an oncologist might use the results.The future potential of liquid biopsy advancements.
“We are obsessed with patient experience and outcomes. EBITDA is just a byproduct.”This philosophy has guided MOC Cancer Care and Research Centre to profitable growth while delivering exceptional chemotherapy care through 24 community cancer centers. Founded by four medical oncologists, MOC began with a vision to bridge the massive gap between expensive private hospitals and overcrowded government facilities. Today, MOC is India's largest network of purpose-built centers that focus exclusively on delivering standardized, high-quality cancer care closer to patients' homes.MOC's model built on the two cornerstones of enhancing the cancer patient's journey and improving the medical oncologist's experience has proven remarkably successful. What's even more impressive is their roster of 48 medical oncologists with zero attrition - unheard of in an industry where doctor mobility is the norm.In this conversation with Mayank Khanduja (Partner, Elevation Capital), co-founders Dr Vashisht Maniar, Dr Ashish Joshi and COO Manish Jobanputra discuss their journey of creating a standardized, patient-centric cancer care delivery system.In this episode, you will gain insights on:> Identifying the structural inefficiencies in India's cancer care system> Scaling standardized care across multiple centers> Creating a dual focus on patient journey and caregiver experience> Building doctor satisfaction through autonomy and support> Achieving growth through patient outcomes
In today's episode, Dr. Mitchell Posner, Dr. Sarah Shubeck, and Dr. Jelani Williams on the University of Chicago Medicine's new Comprehensive Cancer Center. Scheduled to open in 2027, the new center is a seven-floor, 575,000-square-foot building planned to have 80 private beds and 90 consultation and outpatient rooms. At the moment, the center is anticipated to see 200,000 outpatient visits and 5000 inpatient admissions annually. This would be the city of Chicago's first freestanding cancer pavilion.How will we ensure that this new center prioritizes the community's needs? In Chicago's South Side, cancer death rates are twice the national average, and cancer is also the second-leading cause of death on the South Side behind heart disease. In this conversation, you'll hear about the center's development, what patients can expect, and most importantly, the Department of Surgery's commitment to ensure the cancer center supports those who are most vulnerable. Dr. Mitchell Posner is the Thomas D. Jones Distinguished Service Professor of Surgery, Chief of the Section of General Surgery, and the Chief Clinical Officer of the University of Chicago Medicine Comprehensive Cancer Center. From clinical trials for cancer treatment to his more than 250 articles, abstracts, and book chapters, Dr. Posner is a leading authority in the management of upper gastrointestinal cancers. He is frequently voted among the country's best doctors. He is the past president of the Society of Surgical Oncology. He is deputy editor of the Annals of Surgical Oncology and section editor for the gastrointestinal cancer section of the journal Cancer. He served as chairman of the Gastrointestinal Committee of the American College of Surgeons Oncology Group (ACOSOG).Dr. Sarah Shubeck is an Assistant Professor in the Department of General Surgery. She is a Breast Surgical oncologist specializing in breast surgery, cancer, and benign disease treatment. In addition to her clinical practice, Dr. Shubeck's research has been published in many journals including Cancer, JAMA Surgery, and Annals of Surgical Oncology.Dr. Jelani Williams is a 5th-year general surgery resident at the University of Chicago. He is an aspiring surgical oncologist and attended the Eastern Virginia Medical School. He has published research on predictive models and surgery for metastatic pancreatic neuroendocrine tumors as well as the use of machine learning to distinguish benign and malignant thyroid nodules amongst other topics. Deep Cuts: Exploring Equity in Surgery comes to you from the Department of Surgery at the University of Chicago, which is located on Ojibwe, Odawa and Potawatomi land.Our executive producer is Tony Liu. Our senior producers are Alia Abiad, Caroline Montag, and Chuka Onuh. Our production team includes Megan Teramoto, Ria Sood, Ishaan Kumar, and Daniel Correa Bucio. Our senior editor and production coordinator is Nihar Rama. Our editorial team also includes Beryl Zhou and Julianna Kenny-Serrano. The intro song you hear at the beginning of our show is “Love, Money Part 2” from Chicago's own Sen Morimoto off of Sooper Records. Our cover art is from Leia Chen.A special thanks this week to Dr. Jeffrey Matthews — for his leadership, vision, and commitment to caring for the most vulnerable in our communities. Let us know — what have you most enjoyed about our podcast. Where do you see room for improvement? You can reach out to us on Instagram @deepcutssurgery. Find out more about our work at deepcuts.surgery.uchicago.edu.
This week on the show, Petrendologist Charlotte Reed talks with Dr. Noah Synder-Mackler, an associate professor at Arizona State University's School of Life Sciences, about dogs needing friends and Brian Morvant, the Program Manager for CancerCare's Pet Assistance & Wellness (PAW) Program, about helping Cancer Patients stay together with their pets.
In this episode of Dear Cancer, I'm Beautiful, we discuss an often-overlooked aspect of cancer care: oral health. Onco-Radioligist Dr. Abida Taher and Pediatric Dentist Dr. Robyn Lesser, the experts behind (un) cancer, join the show to explain why oral care is so important during cancer treatment, how to protect your teeth and gums, and their unique products designed to help maintain oral health. We explore the impact of chemotherapy, radiation, and immunotherapy on oral health, covering common issues like mouth sores, dry mouth, infections, and long-term dental complications. Dr. Taher and Dr. Lesser also discuss why oral health is frequently overlooked in cancer treatment and why that needs to change. They share their unique approach to preventive dental care and the science behind the products they have developed for cancer patients. Tune in for valuable information and practical tips on maintaining your smile, before, during and after cancer treatment!
In this episode of the Veterinary Cancer Pioneers Podcast, host Dr. Rachel Venable welcomes Dr. Duncan Lascelles, a distinguished professor at North Carolina State University and a leading expert in veterinary pain management and surgery. Dr. Lascelles explores the complex relationship between pain and cancer in veterinary patients, highlighting how both cancer and its treatments can cause significant discomfort—and how pain itself may even influence cancer progression. Together, they dive into findings from clinical and laboratory studies and share best practices for pain assessment and management. Dr. Lascelles also emphasizes the importance of early intervention, client education, and the profound impact of effective pain control on patient outcomes and quality of life. Tune in to gain a deeper understanding of how thoughtful pain management can shape the future of veterinary oncology.
In this episode, Dr. Nasha Winters shares her powerful journey with cancer and the urgent need for a paradigm shift in oncology. She explores the limitations of the current cancer care model, the critical role of mitochondria in chronic illness, and why asking different questions is essential for improving patient outcomes. Dr. Winters also introduces MTOMICS, a cutting-edge data platform designed to revolutionize cancer treatment by integrating personalized, data-driven insights. Listen to the full episode to learn more: The standard cancer care model has seen little progress in outcomes since 1971. Cancer is affecting younger populations, signaling the need for new approaches. Mitochondrial health is a cornerstone of cancer and chronic disease management. Integrative medicine offers evidence-based strategies to enhance patient care. Community and collaboration are essential for driving meaningful change. Data-driven, decentralized healthcare models can empower both patients and practitioners. And much more! Tune in to discover how integrative oncology, cutting-edge research, and patient empowerment are reshaping the future of cancer care.
We are delighted to partner with Western Radiation Oncology today, with two of their distinguished radiation oncologists joining us on the Prostate Health Podcast. LDR (Low Dose Rate) prostate brachytherapy has recently been an underutilized treatment for prostate cancer. However, advancements in modern techniques have demonstrated that LDR brachytherapy, a procedure that can be performed quite easily in an ambulatory surgery center, offers high cure rates with minimal long-term complications, making it a convenient, non-invasive option for men with prostate cancer. Today, we chat with Dr. Steven Kurtzman and Dr. Ankit Agarwal, two distinguished radiation oncologists working to expand access to LDR brachytherapy by partnering with urologists to establish new programs across the United States. Drs. Kurtzman and Agarwal are national leaders in targeted real-time intraoperative planned brachytherapy. With over 7,000 implants performed in the past two decades and more than 700 procedures conducted annually, they have managed to preserve this specialized technique despite its limited expansion in recent years. Based primarily in the Bay Area, California, they provide exceptional cancer care while collaborating with urologists, medical oncologists, and prostate cancer specialists across the United States to assist in establishing LDR programs in ambulatory surgery centers nationwide to provide high-quality prostate cancer care. Tune in to learn more about this promising treatment option! Disclaimer: The Prostate Health Podcast is for informational purposes only. Nothing in this podcast should be construed as medical advice. By listening to the podcast, no physician-patient relationship has been formed. For more information and counseling, you must contact your personal physician or urologist with questions about your unique situation. Show Highlights: Who are the most viable candidates for LDR brachytherapy? How the treatments for low, intermediate, and high-risk prostate cancer patients differ The benefits of a combination of brachytherapy and external beam radiation for high-risk prostate cancer patients How factors like urinary function, bowel function, and prostate size can influence men's eligibility for LDR brachytherapy Why prostate size is no longer a limitation for brachytherapy treatment How is the LDR brachytherapy procedure performed? What can patients expect in terms of recovery and side effects following brachytherapy? Post-therapy safety precautions Links: Follow Dr. Pohlman on Twitter and Instagram - @gpohlmanmd Get your free What To Expect Guide (or find the link on our podcast website) Join our Facebook group Follow Dr. Pohlman on Twitter and Instagram Go to the Prostate Health Academy to sign up. You can access Dr. Pohlman's free mini webinar, where he discusses his top three tips to promote men's prostate health, longevity, and quality of life here. Sponsor Links: Western Radiation Oncology Brachytherapy for Prostate Cancer with Dr. Steven Kurtzman and Dr. Ankit Agarwal on YouTube Expanding Treatment Options at Ambulatory Surgical Centers: LDR Brachytherapy for Prostate Cancer
For many cancer patients, the journey to treatment can be just as challenging as the treatment itself. What if that journey could be shortened—by bringing care directly to their homes?In this episode of the podcast, we're joined by Jennifer Hunsey, BSN, RN, Nursing Program Coordinator at Mayo Clinic Florida, to explore the innovative Cancer Care Beyond Walls initiative. This groundbreaking program is bringing oncology treatments directly to patients, minimizing barriers to care, and reducing the burden of travel. Jennifer discusses how the Mayo Clinic uses technology and a patient-centered approach to deliver chemotherapy and supportive care in the comfort of patients' homes.We learn the inspiration behind this initiative, the role of virtual oversight and home health nursing, as well as the challenges faced and the patient experiences that have shaped the program. Jennifer also shares exciting insights into future expansion plans that could reshape how cancer care is delivered.This episode offers a powerful look at the future of oncology care—listen now to discover the Cancer Care Beyond Walls program's impact on patients and the importance of expanding care beyond traditional settings.Jennifer Hunze, BSN, RN, the RN Program Coordinator for Mayo Clinic's Cancer Care Beyond Walls program. With over 20 years of nursing experience—17 of those in oncology—Jen has worked in various roles, including inpatient hematology, infusion nursing, and cancer treatment management. She now leads efforts to develop innovative cancer care delivery models aimed at improving access and the overall patient experience.
Send us a textJoin us for an impactful episode where we sit down with Rochelle Prosser, a powerhouse in healthcare advocacy and the founder of Orchid Healthcare Solutions. Rochelle's life changed dramatically when her family was struck by cancer, leading her to become a fierce advocate for better care. With her extensive background as a neurotrauma ICU nurse, she shares her unique insights into the challenges of navigating the healthcare system from the inside and the outside. Tune in as Rochelle recounts her touching journey, from the heart-wrenching decisions in her daughter's fight against cancer to her husband's own cancer battle. She discusses the three pivotal barriers that hinder access to quality oncology care—knowledge, access, and effective navigation of the healthcare system. Discover the vital importance of being informed and proactive in treatment decisions, the emotional complexities that accompany these journeys, and the monumental efforts needed to advocate for those you love. Through her organization, Rochelle empowers families by providing crucial resources and knowledge to help navigate their cancer journeys. Listen in to understand how her story can inspire change and make an impact on the lives of those facing similar trials. Subscribe, share, and spread the word—let's create a community of informed and empowered patients together!Thanks for tuning in to this episode of Follow The Brand! We hope you enjoyed learning about the latest marketing trends and strategies in Personal Branding, Business and Career Development, Financial Empowerment, Technology Innovation, and Executive Presence. To keep up with the latest insights and updates from us, be sure to follow us at 5starbdm.com. See you next time on Follow The Brand!
In this episode of the Becker's Healthcare Podcast, host Lukas Voss explores cutting-edge advancements in gastric and esophageal cancer care with two leading experts from City of Hope. Surgical Oncologist Dr. Yanghee Woo and Medical Oncologist Dr. Dani Castillo discuss the benefits of a multidisciplinary approach, the impact of robotic-assisted minimally invasive surgery, and the latest clinical trials offering new hope for patients.This episode is sponsored by City of Hope.
Physician executive Shamar Young discusses his article, "Geographic disparities in advanced cancer care: a call for innovation," highlighting the uneven access to emerging cancer treatments across different health care systems. Shamar explores the impact of geography on advanced therapies like theragnostics and transarterial radioembolization (TARE), emphasizing how disparities in expertise, technology, and resources limit patient options. He discusses how specialized third-party services, such as TeleDaaS, can bridge these gaps by centralizing expertise and improving care accessibility. The conversation examines potential solutions for ensuring that all patients receive optimal cancer treatment, regardless of their location. Listeners will gain insights into how innovation in care delivery can reduce health disparities and improve patient outcomes. Our presenting sponsor is DAX Copilot by Microsoft. DAX Copilot, by Microsoft, is your AI assistant for automated clinical documentation and workflows. DAX Copilot allows physicians to do more with less and turn their words into a powerful productivity tool. DAX Copilot automates clinical documentation—making it available in the EHR within minutes—and clinical workflows, including referral letters, after-visit summaries, style and formatting customizations, and more. 70 percent of physicians who use DAX Copilot say it improves their work-life balance while reducing feelings of burnout and fatigue. Patients love it too! 93 percent of patients say their physician is more personable and conversational, and 75 percent of physicians say it improves patient experiences. Discover AI-powered solutions for clinical documentation and workflows. Click here to see a 12-minute DAX Copilot demo. VISIT SPONSOR → https://aka.ms/kevinmd SUBSCRIBE TO THE PODCAST → https://www.kevinmd.com/podcast RECOMMENDED BY KEVINMD → https://www.kevinmd.com/recommended GET CME FOR THIS EPISODE → https://www.kevinmd.com/cme I'm partnering with Learner+ to offer clinicians access to an AI-powered reflective portfolio that rewards CME/CE credits from meaningful reflections. Find out more: https://www.kevinmd.com/learnerplus